Antipodean Pharmaceuticals has initiated the Phase II clinical trial to test the efficacy of its lead compound MitoQ (mitoquinone) for the treatment of Parkinson’s disease in New Zealand and Australia.
MitoQ, based on a novel technology, targets lipophilic cations that transport and concentrate antioxidants into the mitochondria where they accumulate up to 1000 fold.
Patients who meet the diagnosis of Parkinson’s disease, but yet to receive any treatment to relieve symptoms, will be included in the trial, said the company.
The trial will be led by Barry Snow, MD, FRACP, FRCP, HoD of Neurology, Auckland Hospital, and will involve 10 consultant neurologists at the country’s main regional hospitals who will assess and advise potential participants.
Ken Taylor, CEO, Antipodean, said: “Initiating this Phase 2 efficacy study is a major milestone for our company. We believe MitoQ is a promising compound and the study start is testament to quality research and a very efficient drug development program.”
source:
0 comments:
Post a Comment